Two Missing Amino Acids Were Enough to Break AID Function
A new preprint describes an adult-onset case of hyper-IgM syndrome type 2 tied to a heterozygous AICDA nonsense variant, c.589G>T (p.G197*). The mutation truncates activation-induced cytidine deaminase, or AID, by only two C-terminal residues, yet the functional consequence was severe: patient B cells showed a complete block in class-switch recombination and a substantial fall in somatic hypermutation. In a pathway built on precision, the last two amino acids at the protein’s end still mattered enough to collapse antibody diversification.
AID sits at the center of adaptive humoral immunity. It drives the molecular edits that allow activated B cells to switch from IgM to other isotypes and to diversify antigen recognition through somatic hypermutation. When AID fails, the immune system can still generate B cells, but those cells remain trapped in an early functional state, unable to make the antibody classes needed for durable, targeted defense. The result is the classic biology of HIGM2: defective class switching with preserved upstream B-cell activation machinery.
This case adds a sharp edge to that model. The variant was heterozygous, not biallelic, and yet the phenotype emerged in adulthood. Three previously described C-terminal truncation variants have already been linked to autosomal dominant disease, and this new p.G197* allele extends that pattern with an especially minimal structural loss. A two-residue truncation is not a subtle genetic footnote here; it is sufficient to derail an entire immunologic program.
Single-Cell Readouts Showed a B-Cell Program Stuck at the Starting Line
Single-cell sequencing of primary patient B cells captured the functional defect in molecular terms. Class-switch recombination was completely blocked, while somatic hypermutation fell by about 10-fold. Those two findings map directly onto AID biology: class switching requires efficient cytidine deamination at switch regions, and somatic hypermutation depends on the same enzyme to seed antibody diversification in germinal center reactions. When both processes fail together, the defect is not peripheral; it strikes the core of germinal center antibody maturation.
AICDA mRNA expression was balanced between the wild-type and variant alleles, which argues against a simple transcriptional dropout. The problem appeared downstream of transcript abundance. AID protein abundance was reduced to about 56% of normal, even though subcellular localization remained intact. In practical mechanistic terms, the mutant protein still reached the right compartment, but the amount of functional AID available to execute DNA deamination fell below what the cell needed.
That pattern is important because it separates trafficking from enzymatic competence. A protein can localize normally and still fail if stability, folding, or catalytic efficiency is compromised. In this case, the two-amino-acid truncation likely destabilized the protein or weakened its productive function without abolishing nuclear access. The phenotype therefore points to a narrow structural dependency at the C-terminus, where even a minimal truncation can tip the balance from partial activity to clinical failure.
The adult-onset presentation is also clinically meaningful. Immunodeficiency syndromes are often framed as disorders of childhood, yet this case shows that pathogenic antibody-class defects can surface later when immune demand, cumulative infections, or diagnostic drift finally exposes them. Adult recognition matters because patients may spend years with unexplained infection susceptibility before the underlying genetic lesion is identified.
Inducible Germinal Center Culture Restored Switching in Heterozygous Cells
A striking experimental result came from inducible germinal center, or iGB, cultures. Purified naïve B cells from the patient regained class-switch recombination in this platform. The rescue was not universal, however. CRISPR-Cas9 editing of healthy donor B cells confirmed that the iGB system could rescue cells harboring heterozygous AICDA variants, but not homozygous ones.
That distinction is biologically intuitive. In a heterozygous setting, residual wild-type function may be sufficient for the engineered culture environment to support productive switching, especially if the ex vivo system amplifies activation cues that are otherwise limiting in vivo. Homozygous loss, by contrast, leaves no endogenous AID reserve to recover. The finding gives the iGB platform a role as more than a mechanistic assay; it becomes a way to test whether a specific human AICDA variant preserves enough latent function to be therapeutically recoverable.
The work also speaks to the value of patient-derived B-cell systems in rare immunodeficiency. Genotype alone can label a variant, but functional rescue experiments show whether the lesion behaves as a null, a hypomorphic allele, or a dominant-negative defect in context. Here, the data support a dominant effect from a very small structural change at the AID tail end, with enough residual transcription but insufficient protein output and enzymatic activity to sustain normal antibody maturation.
The bedside consequence is straightforward. In adults with recurrent sinopulmonary infections, poor vaccine responses, or otherwise unexplained hypogammaglobulinemia, a minimal AICDA truncation should remain on the differential even when the variant appears tiny on paper. The biology of AID leaves little room for complacency: two missing residues can be enough to shut down class switching, blunt somatic hypermutation, and produce a clinically meaningful antibody deficiency.
This preprint remains limited by its early-stage status and by the narrow focus of a single molecular case. The broader frequency of similar minimal C-terminal truncations, the full spectrum of clinical severity, and the durability of ex vivo rescue all remain open questions. Even so, the mechanistic signal is unusually clean: a near-complete C-terminal trim of AID can be sufficient to cause adult-onset HIGM2.